Występowanie genów transferaz aminoglikozydowych u metycylino-opornych szczepów Staphylococcus aureus

• Autorzy: Mlynarczyk A. , Szymanek-Majchrzak K. , Mlynarczyk G.

Warianty tytułu

EN

Occurrence of aminoglycoside transpherase genes in methicillin-resistant strains of Staphylococcus aureus

• Języki publikacji: PL

Abstrakty

PL

Badano częstość występowania genów: aacA-aphD kodującego acetylo- transferazę/fosfotransferazę AAC(6')-Ie/APH(2")-Ia, aadD kodującego nu- kleotydylotransferazę ANT(4')-Ia oraz aph(3")-IIIa kodującego fosfotransfe- razę APH(3")-IIIa u grupy 50 metycylino-opornych szczepów Staphylococcus aureus (MRSA), izolowanych z próbek materiału klinicznego. Najczęściej wykazywano łączną obecność genów aacA-aphD i aadD.

EN

Fifty MRSA strains originated from clinical specimens were examined by the PCR method, for the presence of three genes: aacA-aphD, aadD oraz aph(3 ")-IIIa. The obtained results were correlated with the susceptibility of the strains to gentamicin, tobramicin, kanamicin, neomicin, amikacin and netilmicin. The susceptibility results were interpreted according with CLSI and EUCAST guidelines. aacA-aphD gene was found in 34 strains, aadD in 27 strains and aph(3")-IIIa was present in 22 strains. In 19 strains (38%) was present one of the investigated genes, in 29 (58%) strains two genes and in two strains (4%) all three genes were found. The most frequent variant was combination of aacA-aphD and aadD genes.

Słowa kluczowe

PL

Staphylococcus aureus; antybiotyki aminoglikozydowe; geny transferaz aminoglikozydowych; opornosc na aminoglikozydy; szczepy bakteryjne; szczepy metycylinooporne

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2010
• Tom: 62
• Numer: 4
• Opis fizyczny: s.289-295,tab.,bibliogr.

Twórcy

autor

Mlynarczyk A.

• Katedra i Zakład Mikrobiologii Lekarskiej, Warszawski Uniwersytet Medyczny, Warszawa

autor

Szymanek-Majchrzak K.

autor

Mlynarczyk G.

Bibliografia

• 1. Ardic N, Sareyyupoglu B, Ozyurt M i inni. Investigation of aminoglycoside modifying enzyme genes in methicillin-resistant staphylococci. Microbiol Res. 2006;161: 49-54
• 2. Clinical and Laboratory Standarts Institute (CLSI) antimicrobial susceptibility testing standards M2-A9 and M7-A7. M100-S18. 2009; 28: 1-181.
• 3. Emaneini M, Taherikalani M, Eslampour MA i inni. Phenotypic and genotypie evaluation of aminoglycoside resistance in clinical isolates of staphylococci in Tehran, Iran Microb Drug Resist 2009; 15: 129-32.
• 4. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2010 http://www.srga. org/Eucastwt/eucastdefinition.htm
• 5. Ida T, Okamoto R, Nonoyama M i inni. Antagonism between aminoglycosides and beta-lactams in a methicillin-resistant Staphylococcus aureus isolate involves induction of an aminoglycoside- modifying enzyme. Antimicrob Agents Chemother 2002; 46:1516-21.
• 6. Ida T, Okamoto R, Shimauchi C i inni. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol 2001 ; 39:3115-21.
• 7. Jeljaszewicz J, Młynarczyk G, Młynarczyk A. Antibiotic resistance in Gram-positive cocci. Int J Antimicrob Agents 2000; 16: 473-8.
• 8. Kelmani Chandrakanth R, Raju S, Patii SA. Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates. Curr Microbiol 2008; 56: 558-62.
• 9. Lowy D. Antimicrobial resistance: the example of S, aureus. Sci Med 2003; 111: 1256-73.
• 10. Młynarczyk A, Młynarczyk B, Kmera-Muszyńska M i inni. Mechanisms of the resistance and tolerance to beta-lactam and glycopeptide antibiotics in pathogenic Gram-positive cocci. Mini-Rev MedChem 2009; 9: 1527-37.
• 11. Młynarczyk A, Młynarczyk G. Molecular mechanisms of resistance to antibacterial drugs in Staphylococcus aureus. Post Mikrobiol 2008; 47: 423-9.
• 12. Mlynarczyk A, Młynarczyk G, Łuczak M. Mechanizmy opornoœci na antybiotyki szczepów MRSA. Zakażenia 2004; 6: 26-30.
• 13. Młynarczyk В, Młynarczyk A, Kmera-Muszyńska M i inni. Mechanisms of resistance to antimicrobial drugs in pathogenic Gram-positive cocci. Mini Rev Med Chem 2010; 10: 928-37.
• 14. Raju S, Kumar OA, Patil SA, Kelmani Chandrakanth R. Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples. World J Microbiol Biotechnol 2010; 26: 171-6.
• 15. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microb Infect 2008; 14: 2-8.
• 16. Fujimura S, Tokue Y, Takahashi H i inni. Novel arbekacin- and amikacin-modifying enzyme ofmethicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2000; 190: 299-303.
• 17. Soussy CJ, Cavallo JD, Chardon H i inni. Comité de l'antibiogramme de la société française de microbiologie recommandations 2008 (Edition de Janvier 2008) Société Française de Microbiologie 2008.
• 18. Weigel LM, Donlan, RM, Shin DH i inni. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51: 231 -8.
• 19. Woodford N. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect 2005; 11:2-21.
• 20. Yadegar A, Sattari M, Mozafari NA, Goudarzi GR. Prevalence of the genes encoding aminoglycoside-modifying enzymes and methicillin resistance among clinical isolates of Staphylococcus aureus in Tehran, Iran. Microb Drug Resist 2009;15: 109-13.